Sign up USA
Proactive Investors - Run By Investors For Investors

Q BioMed's pipeline boosted as tech partner gets funding for glaucoma therapeutic research

Partner Mannin Research Inc has received funding to carry out a proof of concept study for the treatment
Q BioMed's pipeline boosted as tech partner gets funding for glaucoma therapeutic research
The eyes have it...Mannin is researching a new therapeutic for glaucoma

Biotech accelerator firm Q BioMed Inc (OTCMKTS:QBIO) announced further progress in its bid to expand its pipeline.

Partner Mannin Research Inc has received funding to carry out a proof of concept study for a new therapeutic for eye condition  glaucoma, in which the optic nerve is damaged.

The R&D funding comes from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) and the number of potential patients demanding better treatments make this a multi-billion-dollar opportunity, says QBiomed.

The company has licensed the Mannin Tie2 technology, and is collaboratively developing the Tie2 platform for glaucoma, and other indications.

It has the potential to treat several additional, vascular related diseases, such as acute kidney injury, and cardiorenal syndrome.

"As our understanding about the Angiopoietin-Tie2 system grows, I am very excited about the clinical therapeutic possibilities," said Dr. Sarah Quaggin from Mannin.

The new biologic would be an additional product to the Mannin Tie2 pipeline.

Meanwhile,  Q BioMed said development of the MAN-01 small molecule for the treatment of primary open-angle glaucoma continues on-pace and is now at a point where the most active candidates will be selected for final testing and optimization as a soluble, topical eye drop that permeates well into the eye.

It is anticipated that pre-clinical IND enabling studies will begin in the second quarter of 2018.

Shares in New York eased 0.27% to US$3.69.

View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use